UMIN ID: C000000191
Registered date:31/01/2007
Study on Prevention of Gastric Cancer by Early Detection of Helicobacter pylori Infection and Its Eradication(2nd-Term Comprehensive 10-Year Strategy for Cancer Control from the Ministry of Health and Welfare of Japan)
Basic Information
Recruitment status | Complete: follow-up complete |
---|---|
Health condition(s) or Problem(s) studied | Gastritis |
Date of first enrollment | 1995/09/01 |
Target sample size | 750 |
Countries of recruitment | Japan |
Study type | Interventional |
Intervention(s) | * Lansoprazole(30mg/day x 7days) * Clarithromycin(400mg/day x 7days) * Amoxicillin(1,500mg/day x 7days) |
Outcome(s)
Primary Outcome | The degree of atrophic gastritis |
---|---|
Secondary Outcome |
Key inclusion & exclusion criteria
Age minimum | 20years-old |
---|---|
Age maximum | 59years-old |
Gender | Male and Female |
Include criteria | |
Exclude criteria | 1) Patients who suffer from acuteulcer(AGML, etc,) and gastrointestinal ulcer (stage A1-S2) 2)Patients who suffer from pyloric stenosis, perforation, profuse hemorrhage, etc, and indications of surgical therapy 3)Patients with the anamnesis of gastrectomy or vagotomy 4)Patients with gastric adenoma or active malignant tumor in the stomach and other organs 5)Patients with severe complications (cardiac diseases, hepatic diseases, renal diseases, hematological diseases, etc.) 6)Patients who are the continuous users of possibly ulcerogenic drugs (for instance, steroids, non-steroids, salicylates, etc.) 7)Patients who are or may be pregnant, who are lactating and who wish to become pregnant before and after eradication treatment 8)Patients who have the anamnesis of hypersensitivity to antibiotics, proton pump inhibitors, or other drugs which will be used in the present study 9)Patients who have been judged by the physician in charge to be inappropriate as subjects from other reasons |
Related Information
Primary Sponsor | Second-Term Comprehensive 10-Years Strategy for Cancer Control (Ministry of Health and Welfare of Japan):Cancer Prevention |
---|---|
Secondary Sponsor | |
Source(s) of Monetary Support | Second-Term Comprehensive 10-Years Strategy for Cancer Control (Ministry of Health and Welfare of Japan) |
Secondary ID(s) |
Contact
public contact | |
Name | Daizo Saito |
Address | 5-1-1 Tsukiji, Chuo-ku, Tokyo, Japan Japan |
Telephone | 03-3542-2511 |
dsaitoh@ncc.go.jp | |
Affiliation | National Cancer Center Hospital(NCCH) Endoscopy Division |
scientific contact | |
Name | Daizo Saito |
Address | 5-1-1 Tsukiji, Chuo-ku, Tokyo, Japan Japan |
Telephone | 03-3542-2511 |
Affiliation | National Cancer Center Hospital(NCCH) Endoscopy Division |